WCN26-3137 THE IMPACT OF ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITOR TREATMENT ON CARDIAC FUNCTION IN PATIENTS ON MAINTENANCE HEMODIALYSIS WITH CHRONIC HEART FAILURE

Read full text Summarise with VIRAT
Authors: Masashi Mukoyama, Ami Hamaguchi, Akiko Shimasaki, Shuro Umemoto, Hideki Yokoi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan, a novel therapeutic agent for chronic heart failure and hypertension, has demonstrated significant benefits in reducing cardiovascular events and mortality. However, the clinical usefulness in patients with advanced chronic kidney disease, especially end-stage kidney disease (ESKD) on maintenance dialysis, has not been fully defined so far. We investigated the efficacy and safety of sacubitril/valsartan in patients on maintenance hemodialysis who had chronic heart failure and/or hypertension at a single affiliated hospital.

Fields of Study & Subjects

Heart Failure Treatment and Management Dialysis and Renal Disease Management Renin-Angiotensin System Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104981–104981
Publication date
25 March 2026
Language
EN